Welcome to the e-CCO Library!

P465: Do infliximab trough levels differ between adult and paediatric patients with Crohn’s disease in clinical remission?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Cavazza1*, N. Mavroeidi1, A. Steel2, L. Greathead1, W. Kelleher1, M. Wahed1

Created: Thursday, 21 February 2019, 9:14 AM
P465: Efficacy of ustekinumab for induction and maintenance of histological healing in patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Li K.*1, Chan D.1, Pollack P.1, Jacobstein D.1, Brodmerkel C.1, Gasink C.1, Feagan B.G.2, Sandborn W.3, Rutgeerts P.4, De Hertogh G.5

Created: Wednesday, 20 February 2019, 10:36 AM
P465: Health-related quality of life from the Inflammatory Bowel Disease Questionnaire in patients with ulcerative colitis treated with etrasimod in the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Armuzzi, A.(1)*;Rubin, D.T.(2);Schreiber, S.(3);Panés, J.(4);Fellmann, M.(5);Bartolome, L.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Chaparro, M.(10);Dubinsky, M.C.(11);
Created: Friday, 14 July 2023, 11:05 AM
P465: Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Croft1, W. Faubion2, D. Tierens3, J. Dewulf3, D. Bwirire3, D. Stefani-Hunyady4, F. Cataldi*5

Created: Friday, 22 February 2019, 9:49 AM
P465: Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?
Year: 2022
Source: ECCO'22
Authors: Fumery, M.(1);Nancey, S.(2);Filippi, J.(3);Altwegg, R.(4);Hebuterne, X.(3);Boschetti, G.(2);Veyrard , P.(5);Yzet, C.(1);Paul, S.(6);Roblin, X.(5);
Created: Friday, 11 February 2022, 3:52 PM
P465: One year endoscopic and histologic outcomes to tofacitinib therapy in refractory ulcerative colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Verstockt., B.(1,2);Aden, K.(3,4);Alsoud, D.(2);Outtier, A.(1);Sabino, J.(1,2);Rosenstiel, P.(3,4);Vermeire, S.(1,2);De Hertogh, G.(5);Schreiber, S.(3,4);Ferrante, M.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P465: UC trial designed more than 5 years ago in the light of the EMA guideline on the development of new medicinal products for the treatment of ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Laoun*1, R. Hofmann2

Created: Friday, 22 February 2019, 9:41 AM
P466 Is it possible avoid colectomy with rescue dual therapy with vedolizumab plus tacrolimus in ulcerative colitis that losing response to anti-tumour necrosis factor?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Sanchis1, J.R. Molés1, J. Borrás2, J. Rodriguez1, X. Cortés1

Created: Thursday, 30 January 2020, 10:12 AM
P466: Acetarsol is an effective and safe option in the management of refractory ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Argyriou1*, R.J.M. Ingram1, R. Blatt2, P. Wilson2, S. Samuel1, C. Hawkey1, G.W. Moran1,3

Created: Thursday, 21 February 2019, 9:14 AM
P466: Acute Severe Ulcerative Colitis in the modern era: biologic therapy-exposed patients and salvage therapy with intensified infliximab.
Year: 2021
Source: ECCO'21 Virtual
Authors: Fasoulas, K.(1);Soufleris, K.(1);Kafalis, N.(1);Kevrekidou, P.(1);Bouzoukas, S.(1);Stergiou, E.(1);Dimitriadis, N.(1);Chatzopoulos, E.(1);Tzilves, D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P466: Efficacy and safety outcomes in patients with moderate to severe ulcerative colitis stratified by ethnicity and race: a pooled analysis of data from GEMINI 1, VARSITY, and VISIBLE 1
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mukherjee , R.(1);Khan , R.M.Q.(1);Liu , J.J.(2);Ananthakrishnan , A.N.(3);Lichtenstein , G.R.(4)*;Uddin , S.(1);Young , L.(1);Boules , M.(1);Adamson , P.(2);Reeves , V.(5);
Created: Friday, 14 July 2023, 11:05 AM
P466: Real world effectiveness of vedolizumab over one year in inflammatory bowel disease: a meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schreiber S.1, Dignass A.*2, Peyrin-Biroulet L.3, Hather G.4, Demuth D.5, Khalid J.M.6, Loftus E.V.7

Created: Wednesday, 20 February 2019, 10:36 AM
P466: Real-world effectiveness and safety of golimumab in patients with ulcerative colitis: 52-weeks of post-marketing surveillance data in Japan
Year: 2022
Source: ECCO'22
Authors: Nakamura, S.(1);Asano, T.(2);Tanaka, Y.(3);Sugimoto, K.(4);Yoshigoe, S.(5);Suzuki, Y.(6);
Created: Friday, 11 February 2022, 3:52 PM
P466: Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumour necrosis factor alpha therapy: a prospective single-centre open-label study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Hlavaty*, A. Krajcovicova, J. Letkovsky, I. Sturdik, T. Koller, J. Toth, M. Huorka

Created: Friday, 22 February 2019, 9:49 AM
P466: Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn1, J. Panés*2, R. Panaccione3, G. R. D’Haens4, B. E. Sands5, C. Su6, M. Moscariello6, T. V. Jones6, R. D. Pedersen6, G. S. Friedman6, N. Lawendy6, G. Chan6

Created: Friday, 22 February 2019, 9:41 AM
P467 Can induction and maintenance serum vedolizumab levels predict long-term clinical outcome in inflammatory bowel disease (IBD)?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Miller1, H. Morgan2, A. Steel3, M. Wahed4

Created: Thursday, 30 January 2020, 10:12 AM
P467: 5-ASA is not superior to no-maintenance in patients with newly diagnosed Crohn's disease - a nationwide cohort from the epi-IIRN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Atia, O.(1);Goren, I.(2)*;Sharar Fischler, T.(2);Loewenberg Weisband, Y.(3);Greenfeld, S.(4);Kariv, R.(5);Ledderman, N.(6);Matz, E.(7);Magen Rimon, R.(8);Dotan, I.(2);Turner, D.(1);Yanai, H.(2);
Created: Friday, 14 July 2023, 11:05 AM
P467: A comparison of thiopurines vs. anti-TNF-α therapy in steroid-dependent ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Hosomi*, M. Ohira, H. Yamagami, R. Nakata, N. Sugita, Y. Nishida, S. Itani, T. Yukawa, N. Kamata, K. Otani, Y. Nagami, F. Tanaka, K. Taira, T. Tanigawa, T. Watanabe, Y. Fujiwara

Created: Thursday, 21 February 2019, 9:14 AM
P467: Circulating CD8 α4β7+ and CD8b7+ memory T cells as early biomarkers of clinical response to vedolizumab in ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Gonzalez-Vivo1, M. K. Lund Tiirikainen2, C. de Jesús Gi2, E. Ruiz-Romeu2, L. Sans2, L. Canillas1, M. Andreu1, L. F. Santamaria-Babí2, L. Marquez*1

Created: Friday, 22 February 2019, 9:41 AM
P467: Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panés J.*1, Rubin D.T.2, Vermeire S.3, Lindsay J.O.4, Sands B.E.5, Su C.6, Friedman G.6, Zhang H.6, Kayhan C.6, Manuchehri A.7, Healey P.8

Created: Wednesday, 20 February 2019, 10:36 AM